October 2002

|
Volume 14 Issue 10
Dean Kereiakes: I will be discussing the clinical and economic issues surrounding drug-eluting stents and the evolving role of vascular brachytherapy. The father of coronary angioplasty, Andreas Gruentzig, once said: “if I had an enemy, I would teach…
Greg Braden: Thank you, Bill. I appreciate the opportunity to be here and share this webcast with you. We will briefly discuss the clinical efficacy of vascular brachytherapy and review our own local experience, much like what Dean has shown in Chris…
Stephen Ramee: Thank you very much for inviting me, Bill. It is important to think of the opportunities for vascular brachytherapy beyond the heart because although the heart is clearly where we all train, cardiology programs in general have had tunn…
May 14, 2002 William O’Neill: There is a question for Dean Kereiakes. How will decreasing or eliminating restenosis impact surgical volume — obviously a major concern for surgeons and hospitals because coronary bypass surgery is a very profitable se…
May 15, 2002 Scott McMahon: Our first question is as follows: Do drug-eluting stents eliminate the need for IIb/IIIa platelet inhibitors and their associated costs which are reimbursed in DRG 516? William O’Neill: Dean, could you comment on that? Y…
May 16, 2002 Scott McMahon: The first question this evening is as follows: What is your estimate of the aggregate increase or decrease in PCI procedures at one, two and five years following the introduction of drug-eluting stents? William O’Neill:…
On May 14–16, 2002, the program “In-Stent Restenosis: Treatment Controversies” was broadcast live via web cast and audio conference. The following supplement is a transcript of the data presented during the program, as well as the questions and answe…
William O’Neill: We will begin by spending about 40 minutes discussing some exciting new advances in the treatment of restenosis. Also, we will discuss drug-eluting stents and their issues in the cath lab. We will then devote a good deal of time and…